Skip to main content

Noema Pharma raises 54 million Swiss francs

| News

Noema Pharma raises 54 million Swiss francs

01.12.2020

The Basel-based pharmaceutical company Noema Pharma has raised a total of 54 million Swiss francs as part of a Series A financing round. This should help to advance the clinical development of drugs aimed at fighting rare neurological disorders.

Noema Pharma develops drugs to treat rare neurological disorders that arise on account of imbalanced neuronal networks. Clinical development can now be advanced for four relevant product candidates after Noema Pharma successfully closed a financing round by raising a total of 54 million Swiss francs, as detailed in a press release. In addition, the Basel-based pharma group Roche has now received a shareholding in Noema in exchange for rights to the four product candidates. These aim to combat “seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders”.

“The successful licensing of these exciting clinical-stage product candidates from Roche, together with our up-sized CHF 54 million Series A financing, will enable Noema to reach value-creating development milestones with all four products”, comments Luigi Costa, CEO of Noema, in the press release, before adding: “We are honored to have garnered continued support from our seed investor, Sofinnova Partners, and to have attracted Polaris Partners as a co-lead investor. We are equally pleased to welcome highly experienced specialist investors Gilde Healthcare, Invus and BioMed Partners”.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, and Darren Carroll, Partner at Polaris Partners, will both become members of the newly formed Board of Directors at Noema Pharma. While Papiernik underlined the work conducted by Noema up to this point that has aimed “to bring ground-breaking therapies to patients with debilitating neurological disorders”, Carroll, for his part, described the company as a “prime example of the exceptional pharma-grade assets Europe has to offer, along with a flourishing talent pool”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

An intense and ambitious year for the Jura site of the Switzerland Innovation Park Basel Area

Despite the coronavirus pandemic, which has delayed some projects, the Jura site of the Switzerland Innovation Park Basel Area has...
Read More

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...
Read More

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...
Read More

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!
Read More

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...
Read More

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...
Read More
1 30 31 32 33 34 41

Do you have a question? We'd like to hear from you.